Skip to main content
Fig. 8 | Molecular Medicine

Fig. 8

From: The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma

Fig. 8

Tumor microenvironment (TME) in high- and low-ARGs signature score groups in PRAD cohort. A Comparison of the immune score, stromal score, and ESTIMATE score between the high- and low-ARGs signature score groups. B The immune profiles of high- and low-ARGs signature score groups. C Comparison of infiltrating immune cells between high- and low-ARGs signature score groups. D Differential expression of immune checkpoint genes (PD-L1, PD-1, CTLA4, TIM3) between high- and low-ARGs signature score groups. E Correlation analysis between the expression level of immune checkpoint genes (PD-L1, PD-1, CTLA4, TIM3) and the ARGs signature score. F Correlation analysis between the signature-related ARG and immune checkpoint genes. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, cor.sp represented “Spearman Correlation Coefficient”)

Back to article page

Molecular Medicine

ISSN: 1528-3658